This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Forkhead box O1 (FOXO1)	<p>Mouse studies suggest FOXO1 inhibition could convert pancreatic δ cells into β cells to help treat diabetes. In juvenile but not adult mice with β cell ablation, Foxo1 was downregulated in δ cells and somatostatin-producing δ cells were converted into insulin-producing β cells. In adult mice with β cell ablation, a Foxo1 inhibitor induced δ-to-β-cell conversion and increased the percentage of insulin-producing β cells compared with no treatment. Next steps include identifying modulators of FOXO1 or FOXO family-binding partners and associated signaling networks.</p> <p>SciBX 7(35); doi:10.1038/scibx.2014.1041 Published online Sept. 11, 2014</p>	Patent application filed; available for licensing from the University of Geneva Technology Transfer Office	<p>Chera, S. <i>et al. Nature</i>; published online Aug. 20, 2014; doi:10.1038/nature13633</p> <p>Contact: Pedro L. Herrera, University of Geneva, Geneva, Switzerland e-mail: pedro.herrera@unige.ch</p>